The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis

References

• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584–593
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Hayman S, Gertz M A, Dispenzieri A, Lacy M Q, Greipp P R, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826–831
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Torjman L, Ben Romdhane N, Ladeb S, El Omri H, Ben Othman T, et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005; 36: 193–198
   PubMed Web of Science ®Google Scholar
• Rajkuma S V, Blood E, Vesole D, Fonseca R, Greipp P R, for the Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39
   PubMed Web of Science ®Google Scholar
• Alvares C L, Davies F E, Horton C, Patel G, Powles R, Sirohi B, et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol 2005; 129: 607–614
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, et al. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica 2002; 87: 934–942
   PubMed Web of Science ®Google Scholar
• Ahmad I, Islam T, Chanan-Khan A, Hahn T, Wentling D, Becker J L, et al. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant 2002; 29: 577–580
   PubMed Web of Science ®Google Scholar
• Milone H, Prates V, Bordone J, Napal J, Garcia C. Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD. Bone Marrow Transplant 2003; 32: 343
   PubMed Web of Science ®Google Scholar
• Patriarca F, Sperotto A, Prosdocimo S, Geromin A, Zaja F, Fanin R. Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients. Haematologica 2003; 88: 597–599
   PubMed Web of Science ®Google Scholar
• Kroff M H, Lang N, Bisping G, Domine N, Innig G, Hentrich M, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607–616
   PubMed Web of Science ®Google Scholar
• Dimopoulos M A, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112–117
   PubMedGoogle Scholar
• Garcia-Sanz R, Gonzalez-Porras J R, Hernandez J M, Polo-Zarzuela M, Sureda A, Barrenetxea C, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J, Goldstone A H, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005; 129: 763–770
   PubMed Web of Science ®Google Scholar
• Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568–1574
   PubMed Web of Science ®Google Scholar